Home > Boards > US OTC > Biotechs >

VistaGen Therapeutics, Inc. (VTGN)

VTGN RSS Feed
Add VTGN Price Alert      Hide Sticky   Hide Intro
Moderator: whosjohngalt
Search This Board: 
Last Post: 5/21/2022 6:23:33 AM - Followers: 97 - Board type: Free - Posts Today: 0

VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. Our CNS portfolio includes three differentiated drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications.

Company WebsiteVistaGen Therapeutics, Inc. (VTGN)                                                                                               Press ReleasesPress Releases :: VistaGen Therapeutics, Inc. (VTGN)

FinancialsAll SEC Filings :: VistaGen Therapeutics, Inc. (VTGN)                                                                                 Leadership TeamLeadership :: VistaGen Therapeutics, Inc. (VTGN)

Current Stock PriceQuote :: VistaGen Therapeutics, Inc. (VTGN)                                                                               

 

Pipeline

Our CNS pipeline includes three differentiated new generation CNS drug candidates with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of our drug candidates, PH94B, PH10 and AV-101, has a novel mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential for multiple indications in large mental health and neurology markets.

PH94B Neuroactive Nasal Spray

PH94B is an innovative investigational synthetic neuroactive pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with benzodiazepines. PH94B’s rapid-onset mechanism of action is fundamentally different from benzodiazepines and all other FDA-approved anti-anxiety medications. Developed from proprietary compounds called pherines and administered at non-systemic microgram doses as an odorless nasal spray, PH94B binds to nasal chemosensory receptors which activate neural circuits in the limbic amygdala that suppress fear and anxiety. Following a highly statistically significant (p=0.002) Phase 2 study of PH94B in adults with social anxiety disorder (SAD), and a successful meeting with the U.S. Food and Drug Administration (FDA), we are currently preparing for pivotal Phase 3 development of PH94B for the acute treatment of anxiety in adults with SAD.

The FDA has granted Fast Track designation for development of PH94B for SAD, the first such designation ever granted by the FDA for a SAD drug candidate. In a manner analogous to a rescue inhaler used before an asthma attack, PH94B has potential to be used by a person with SAD before an anxiety-provoking stressor.

Based on the results of Phase 2 studies, PH94B has the potential to be the first FDA-approved acute (on-demand) treatment of anxiety for millions who suffer from SAD. In addition, PH94B has potential in postpartum anxiety, preoperative anxiety, PTSD, panic disorder, and generalized anxiety disorder.

PH10 Neuroactive Nasal Spray

PH10 is a synthetic investigational neuroactive pherine nasal spray with a novel, rapid-onset mechanism of action that is fundamentally different from all current treatments for depression. Developed from proprietary compounds called pherines and administered at microgram doses as an odorless nasal spray, PH10 binds to nasal chemosensory receptors which activate neural circuits in the brain that produce antidepressant effects. Specifically, a microgram level dose of PH10 (6.4 mcg) engages specific nasal chemosensory neurons (NCNs). NCNs activate olfactory bulb neurons (OBNs) on the base of the brain. OBNs send neural connections to neurons in the central limbic amygdala, the brain center where mood is regulated. Neurons in the limbic amygdala stimulate release of excitatory neurotransmitters (glutamate, norepinephrine) resulting in rapid-onset antidepressant effects. Systemic uptake and distribution are not required to produce rapid-onset antidepressant effects. In a small exploratory randomized, double-blind, placebo-controlled Phase 2A clinical study in major depressive disorder (MDD), at a 6.4 mcg dose, rapid-onset antidepressant effects were observed and sustained for 8 weeks (p=0.022), without psychological side effects or safety concerns associated with ketamine-based therapy.

AV-101, an Oral NMDAR Glycine Site Antagonist

AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators. The NMDA receptor is a pivotal receptor in the brain and abnormal NMDA function is associated with multiple CNS diseases and disorders, including MDD, epilepsy, levodopa-induced dyskinesia, neuropathic pain and many others. AV-101 is an oral prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), which binds uniquely at the glycine site of the NMDA receptor and has potential to be a new treatment for multiple CNS indications involving NMDA receptors, each with high unmet need.

Recent discoveries from successful AV-101 preclinical studies demonstrate a multi-fold concentration increase in the brain of AV-101 prodrug, and, more importantly, of 7-Cl-KYNA, AV-101's active metabolite, when AV-101 is administered adjunctively with probenecid, a safe and well-known oral anion transport inhibitor used to treat gout. This data suggest that it may be possible to increase therapeutic concentrations and duration of 7-Cl-KYNA in the brain, and thus increase NMDAR antagonism in patients when AV-101 and probenecid are combined.

VistaGen Investor Contact
Mark McPartland
VistaGen Therapeutics
Phone: (650) 577-3606

EmailIR@vistagen.com
 

VTGN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VTGN News: VistaGen to Participate in Upcoming June Investor Conferences 05/27/2022 04:30:00 AM
VTGN News: Statement of Changes in Beneficial Ownership (4) 05/16/2022 09:40:14 AM
VTGN News: Current Report Filing (8-k) 05/03/2022 01:12:37 PM
VTGN News: Statement of Changes in Beneficial Ownership (4) 05/03/2022 01:11:18 PM
VTGN News: Initial Statement of Beneficial Ownership (3) 05/03/2022 01:08:47 PM
PostSubject
#4751   eh picked up another 1k this week, small fry whosjohngalt 05/21/22 06:23:33 AM
#4750   think so yup whosjohngalt 04/15/22 03:27:28 PM
#4749   2022 should be a great year for us....Here Rafa636 02/11/22 10:08:05 AM
#4748   all is well here whosjohngalt 02/10/22 05:26:07 PM
#4747   Nice finish today TurdBlossom 01/24/22 03:57:47 PM
#4746   good start whosjohngalt 01/03/22 04:56:04 PM
#4745   Nice volume!!! 1 of the Phase Johnny_C 12/27/21 04:04:17 PM
#4744   Short positions are closing and institutional holdings now Johnny_C 12/03/21 03:06:10 PM
#4743   Institutions buying heavy, institutional ownership jumped from 53% Johnny_C 12/03/21 10:09:29 AM
#4742   yep agree on 2022, just sleeping on this company. whosjohngalt 12/03/21 05:12:46 AM
#4741   Board seems quite lately. I think 2022 will Johnny_C 12/02/21 08:42:45 PM
#4740   all good whosjohngalt 11/10/21 04:44:23 PM
#4739   Yup, like several other holdings patience hopefully pats Johnny_C 11/04/21 10:19:24 AM
#4738   all is good. whosjohngalt 11/03/21 06:44:43 PM
#4737   Nice volume at close Johnny_C 11/03/21 05:35:46 PM
#4736   agree figure mid next year just sleeping on this, whosjohngalt 10/13/21 04:56:25 PM
#4735   I think the wait will be less than Johnny_C 10/13/21 12:19:54 PM
#4734   like a circus whosjohngalt 10/05/21 05:01:30 PM
#4733   VistaGen is a no brainer whosjohngalt 10/05/21 09:15:41 AM
#4732   some pretty big hitter buying into the bell to whosjohngalt 09/18/21 08:20:35 AM
#4731   seems a bunch whosjohngalt 09/13/21 04:12:03 PM
#4730   nice update whosjohngalt 09/13/21 08:02:31 AM
#4729   nice to see 3's again whosjohngalt 08/28/21 07:07:10 AM
#4728   would add whosjohngalt 08/14/21 08:43:22 AM
#4727   sure sounds whosjohngalt 08/14/21 08:33:31 AM
#4726   Been trading $MNRA options this week, what did Richard2 08/13/21 09:04:52 AM
#4725   good conference call whosjohngalt 08/13/21 07:55:04 AM
#4724   Price holding up nicely here Richard2 08/05/21 10:47:22 AM
#4723   probably an update whosjohngalt 08/05/21 10:45:58 AM
#4722   Close e fucking nough, of course if it Richard2 08/02/21 09:34:14 PM
#4721   I’ve been watching for years, not new. Richard2 07/31/21 08:29:27 AM
#4720   thanks good to see new people here, we work whosjohngalt 07/31/21 06:05:04 AM
#4719   I’m giving you a follow just because of Richard2 07/30/21 08:35:25 PM
#4718   new big hitter added to board whosjohngalt 07/22/21 08:17:15 AM
#4717   nice good to see you back then, and I'm whosjohngalt 07/02/21 04:34:38 AM
#4716   Greetings to all. I was here with an TurdBlossom 07/02/21 01:18:28 AM
#4715   new 52 week high whosjohngalt 07/01/21 04:52:04 PM
#4714   3's up whosjohngalt 06/30/21 04:14:08 PM
#4713   new exchange Monday whosjohngalt 06/25/21 10:23:14 AM
#4712   Russell 2000 index done whosjohngalt 06/16/21 09:38:18 AM
#4711   nice week whosjohngalt 06/11/21 04:41:10 PM
#4710   1 yr for a phase 3 trial is Johnny_C 06/06/21 08:21:22 PM
#4709   figured that was coming really whosjohngalt 05/26/21 03:22:07 PM
#4708   A sell of the news - ouch. JohnLocke101 05/26/21 02:12:17 PM
#4707   VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of JohnLocke101 05/26/21 08:39:45 AM
#4706   nice week whosjohngalt 05/21/21 04:32:23 PM
#4705   * * $VTGN Video Chart 05-20-2021 * * ClayTrader 05/20/21 04:29:01 PM
#4704   MAY 12....IT'S A SHELF PLACEMENT > READ THE crudeoil24 05/20/21 10:09:09 AM
#4703   This is old news and is part of Johnny_C 05/20/21 08:51:51 AM
#4702   $75M > dilution > SEC filing 424B5 crudeoil24 05/19/21 05:15:36 PM
PostSubject
Consent Preferences